Nadroparin calcium

Nadroparin calcium
Clinical data
Trade names	Fraxiparin(e), Fraxodi, others
AHFS/Drugs.com	International Drug Names
Routes of; administration	Subcutaneous injection (except for haemodialysis)
ATC code	B01AB06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only;
Pharmacokinetic data
Bioavailability	89% (SC dose)
Elimination half-life	3.7 hours (SC dose)
Excretion	clearance 21.4mL/min (+/- 7)
Identifiers
	IUPAC name (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate;
CAS Number	9005-49-6 ;
DrugBank	DB08813 ;
ChemSpider	none;
UNII	1K5KDI46KZ;
KEGG	D07510 ;
CompTox Dashboard (EPA)	DTXSID20872761 ;
ECHA InfoCard	100.029.698
Chemical and physical data
Molar mass	4300 g/mol
	(what is this?) (verify)

Nadroparin (trade names Fraxiparin[e], Fraxodi, among others) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by Sanofi-Synthélabo.

Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.^[1]

For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the abdomen. It is on the World Health Organization's List of Essential Medicines.^[2]

References

^ "Fraxiparine PRODUCT MONOGRAPH (Canada)" (PDF). Aspripharma.com. Retrieved 2 April 2019.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

External links

"NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Retrieved 2 April 2019.
Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. doi:10.1159/000096484. PMID 17057417. S2CID 95878036.